Summary of Purpose
To determine whether suloctidil would influence the subsequent recurrence of stroke, the occurrence of myocardial infarction, or cardiovascular death in patients suffering previously from thromboembolic stroke.Read More →
The following dates are available for this trial. Trial information last updated on 1 March 2001.
|Start Date||First Received||1st Completion||Completion||Verification||Results|
- Continental Pharma, Belgium.
Randomized, double-blind, placebo-controlled trial of 438 patients at 4 centers.